Trevyent (treprostinil PatchPump) / Correvio, United Therapeutics Corporation - LARVOL DELTA

EARLY AND HIGH-DOSE TREPROSTINIL THERAPY TARGETING PRESSURE TO IMPROVE RIGHT VENTRICULAR FUNCTION IN PULMONARY ARTERIAL HYPERTENSION: ARTISAN INTERIM ANALYSIS (ACC 2026) - P4 | "Early high-dose treprostinil therapy targeting reduced afterload demonstrates significant RV functional improvement and cardiac reverse remodeling at 12 months. Sponsored by United Therapeutics."

Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

Artisan Interim Analysis: Early and High-Dose Treprostinil Reduces mPAP and Improves Right Heart Function in PAH (ISHLT 2026) - P4 | "These findings support earlier, aggressive PAH treatment to potentially alter disease trajectory via pressure-targeted therapy as part of a broader multiparametric risk assessment. Sponsored by United Therapeutics."

Cardiovascular

Patient Reported Experience of Participants in the ARTISAN Study for Pulmonary Arterial Hypertension (PAH) (ATS 2025) - "This abstract is funded by: United Therapeutics Objective: The ARTISAN study is an ongoing Phase 4 study evaluating an aggressive 'treat to pressure' approach to reduce mean pulmonary pressure (mPAP) using parenteral treprostinil and CardioMEMS as a daily pressure monitoring device... Seventeen of 27 (63%) possible Patient Questionnaires were received. Of these, 41%(7/17) respondents expressed some concerns prior to participation in the study, while the majority (88%; 15/17) stated that pre-teaching and home health visits with a nurse before participation better prepared them and ameliorated their concerns for participation in the study. For questions related to concerns during participation, 71% (12/17) responded that they were able to manage everyday tasks, while the remaining 29% had various levels of difficulty."

Clinical • Cardiovascular • Pulmonary Arterial Hypertension • Respiratory Diseases

NAVIGATING THE MANAGEMENT CONUNDRUM: A CASE OF SEVERE PULMONARY ARTERY HYPERTENSION WITH A GIANT ATRIAL SEPTAL DEFECT (CHEST 2024) - "Intravenous treprostinil deferred due to hemodynamic instability...Sildenafil has demonstrated efficacy in reducing PAH and PVR by vasodilating pulmonary arteries, thereby improving exercise capacity and hemodynamics prior to closure [5,6].Severe pneumonia complicates PAH management by raising PVR, increasing RVF risk and V/Q mismatch... In conclusion, managing severe PAH with a giant ASD posed significant challenges. Despite interventions like iNO and dobutamine, PVR reversibility and pneumonia complicate treatment decisions. Immediate ASD closure benefits, but medical optimization is crucial."

Clinical • Cardiovascular • Cough • Heart Failure • Hypertension • Infectious Disease • Pain • Pneumonia • Pulmonary Arterial Hypertension

A MISSED DIAGNOSIS OF CONGENITAL HEART DISEASE (CHEST 2024) - "With infection recovery she began medical management with PAH targeted therapy (ambrisentan, and sildenafil) and midodrine. With discharge she was transitioned to tadalafil with plans to initiate inhaled treprostinil... PAH persists as a notable complication in adults with CHD, yet improved detection and management of congenital cardiac issues in developed nations have reduced the occurrence of ES in adults. Nevertheless, cases like the one illustrated emphasize that even in the US CHD can be missed. Sustained attention and advancements in treatment strategies are crucial to enhance outcomes for individuals navigating this intricate constellation of conditions."

Atrial Fibrillation • Cardiovascular • Heart Failure • Infectious Disease • Novel Coronavirus Disease • Pulmonary Arterial Hypertension • Respiratory Diseases • Thrombosis

Beyond the High: The Association Between Cocaine Use and Severe Pulmonary Arterial Hypertension in a 48-year-old Patient (ATS 2024) - "Urine toxicology was positive for cannabis, cocaine, and fentanyl...Potential mechanisms include inhibition of sympathetic neurotransmitters (norepinephrine, dopamine and serotonin) reuptake at synaptic junctions, direct stimulation of endothelial cells, and the release of potentvasoconstrictors such as Endothelin-1 augmenting the pulmonary vasculature. The paradoxical equilibrium between severely elevated PA pressures and minor clinical symptoms is an uncommon phenomenon that resolved quickly upon abstinence from cocaine use and therapy with oral Tadalafil."

Clinical • Cardiovascular • Gastroenterology • Hepatology • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • EDN1

ARTISAN: A NOVEL STUDY OF MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION (ACC-WCC 2023) - "After initiating parenteral treprostinil with rapid dose titration based on mPAP assessment, subjects may transition to oral treprostinil with continuing upward dose titration to further reduce mPAP... The prospectively designed ARTISAN clinical trial aims to explore the hypothesis that early and rapid treprostinil afterload-lowering therapy results in a disease modifying treatment option for PAH."

Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

[VIRTUAL] CLINICAL IMPACT OF LIQ861 THROUGH ASSESSMENT BY THE CARDIOMEMS SYSTEM IN PULMONARY ARTERIAL HYPERTENSION: A CASE STUDY (CHEST 2020) - "The INSPIRE trial (Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil) is a Phase 3, open-label, multicenter study to evaluate the long-term safety and tolerability of LIQ861 for PAH...The patient refused parenteral prostacyclins and was initiated on tadalafil and ambrisentan... This case illustrates an additive and favorable clinical, hemodynamic, and RV remodeling response to LIQ861 and the utility of the CardioMEMS™ system to monitor disease progression. CLINICAL IMPLICATIONS: The combination of CardioMEMS™-derived hemodynamic and adjunctive clinical information can inform clinical decisions regarding advancement in therapy and optimizing clinical status."

Clinical • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension

Resolution of Pulmonary Arterial Hypertension (PAH) in a Patient with GATA-2 Deficiency Following Bone Marrow Transplant (BMT) (ATS 2019) - "...Treatment was initiated with sildenafil 20 mg three times daily and subsequently inhaled treprostinil 9 puffs four times daily...Post-transplant course was complicated by mucositis, pyelonephritis, ileus, and acute dermal GVHD.100 days post-transplant, Pro-BNP and RVSP were normal, treprostinil was weaned off and subsequently tadalafil was discontinued...Animal models suggest a mechanism of bone marrow-derived cells affecting BMPR2 expression. Future research may expand the role of bone marrow in pulmonary vasculopathy."

Clinical